All these results indicate that COMP-induced M2 macrophage infiltration impaired the high activity of antitumor immune processes, and the treatment targeting COMP may reverse the M2 immunosuppression phenotype and be instrumental for immunotherapy in colon cancer patients. The gene discussed is COMP; the disease is malignant colon neoplasm.